{
  "items": [
    {
      "title": "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma",
      "description": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with HR-SMM was submitted to the FDA in November 2024.",
      "published_utc": "2025-05-21T06:21:00",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=c10d3e935f1da769afe8a3b36ecf11a8d40b61fa4022a0abe4b2353c8419d36b",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 134628232,
      "datetime": 1747779660
    },
    {
      "title": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
      "description": "",
      "published_utc": "2025-05-21T04:02:11",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4",
      "category": "company",
      "image": "",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 134620526,
      "datetime": 1747771331
    },
    {
      "title": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "description": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "published_utc": "2025-05-21T02:47:00",
      "source": "MarketWatch",
      "url": "https://finnhub.io/api/news?id=73e8398f321ff127b9afd3cb532b8f702c784e51f153a98550298bb317a3c41c",
      "category": "company",
      "image": "",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 134633143,
      "datetime": 1747766820
    },
    {
      "title": "Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference",
      "description": "Johnson &amp; Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ETCorporate ParticipantsJoe Wolk - EVP, Chief...",
      "published_utc": "2025-05-20T23:10:55",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=74bf315e087a1a7e595c1e798036a55ca2777247c2180cf6c5e8d2c5ac9f4553",
      "category": "company",
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 134618698,
      "datetime": 1747753855
    },
    {
      "title": "Transcript : Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 01",
      "description": "Presenter SpeechShagun Singh Chadha Hello, everyone. I am Shagun Singh, Senior Research Analyst at RBC. And I'm very happy to host the next session with Johnson & Johnson. Joining us from the",
      "published_utc": "2025-05-20T22:35:23",
      "source": "Finnhub",
      "url": "https://finnhub.io/api/news?id=124f6229ae3e21f9876803f4b8347b9a66650f5ade72680ee59987d33c7b4663",
      "category": "company",
      "image": "",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 134615154,
      "datetime": 1747751723
    }
  ],
  "metadata": {
    "cached_at": "2025-09-25T07:46:13.819367+00:00",
    "cache_key": "news_2fecb72a09456d276e158816b21add80",
    "count": 5
  }
}